• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Harvard Bioscience Inc.

    5/27/25 4:36:27 PM ET
    $HBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $HBIO alert in real time by email
    SD 1 sd_52725.htm FORM SD

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM SD

     

    SPECIALIZED DISCLOSURE REPORT

     

     

    Harvard Bioscience, Inc.

    (Exact name of the registrant as specified in its charter)

     

    DELAWARE 001-33957 04-3306140
    (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number)

     

    84 October Hill Road, Holliston, MA 01746
    (Address of Principal Executive Offices) (Zip Code)

     

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.
    ☐Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended December 31, 2024.

     

     

     

     

    Section 1 - Conflict Minerals Disclosure

     

    Item 1.01 Conflict Minerals Disclosure and Report

     

    Conflict Minerals Disclosure

     

    This Form SD of Harvard Bioscience, Inc. (the “Company”) is filed pursuant to Rule 13p-1 promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period January 1, 2024 to December 31, 2024.

     

    A copy of the Company’s Conflict Minerals Report is filed as Exhibit 1.01 hereto and is publicly available at: http://investor.harvardbioscience.com/corporate-governance.cfm.

     

    The content of any website referred to in this Form SD or in the attached Conflict Minerals Report is included for general information only and is not incorporated by reference in this Form SD or in the Conflict Mineral Report.

     

    Item 1.02 Exhibit

     

    Harvard Bioscience, Inc. is hereby filing its Conflict Minerals Report as Exhibit 1.01 to this Form SD.

     

    Section 3 – Exhibits

     

    Item 3.01 Exhibits

     

    The following exhibit is filed as part of this report.

     

    Exhibit 1.01 Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

    Harvard Bioscience, Inc.  

     (Registrant)

     

    /s/ John Fry May 27, 2025  
    By:

    John Fry

    Chief Legal Counsel

       
           
    Get the next $HBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HBIO

    DatePrice TargetRatingAnalyst
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/10/2023$3.00 → $4.00Speculative Buy → Buy
    The Benchmark Company
    More analyst ratings